Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Initial management of discoid lupus and subacute cutaneous lupus

Jennie Clarke, MD
Section Editor
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor
Abena O Ofori, MD


Discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) are variants of cutaneous lupus that may occur independently or as manifestations of systemic lupus erythematosus. DLE most commonly occurs on the head and is characterized by well-defined inflammatory plaques that evolve into atrophic, disfiguring scars (picture 1A-B). SCLE typically presents with erythematous, scaly papules or annular plaques on the neck, upper trunk, and arms (picture 2A-B).

Concern over the appearance of skin lesions leads most patients with DLE or SCLE to desire treatment, and the majority will respond to photoprotection combined with topical antiinflammatory agents or systemic antimalarial drugs. In particular, early treatment of DLE is essential to minimize scarring.

The initial approach to the treatment of patients with DLE or SCLE will be discussed here. The clinical manifestations of DLE and SCLE and the management of patients with refractory disease are discussed separately. (See "Overview of cutaneous lupus erythematosus", section on 'Discoid lupus erythematosus' and "Overview of cutaneous lupus erythematosus", section on 'Subacute cutaneous lupus erythematosus' and "Management of refractory discoid lupus and subacute cutaneous lupus".)


Although most individuals with DLE or SCLE require pharmacologic therapy to treat active skin lesions, the elimination of exacerbating factors is an important component of long-term management. Strict photoprotection should be recommended, and photosensitizing medications should be discontinued if feasible. The possibility of drug-induced disease also needs to be considered in patients who present with SCLE, and should prompt discontinuation of any potential offending agents. (See 'Nonpharmacologic measures' below.)

For most patients with DLE or SCLE, topical corticosteroids are an appropriate first-line therapy (algorithm 1). Topical calcineurin inhibitors, which lack the atrophogenic effects of corticosteroids, have also been shown to be effective for the treatment of cutaneous lupus. However, topical calcineurin inhibitors are more expensive than many topical corticosteroids, and may have a slower onset of action. Intralesional corticosteroid injections can be used to treat patients with focal lesions that do not respond to topical treatment. (See 'Local therapy' below.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: May 16, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Kuhn A, Ruland V, Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus 2010; 19:1036.
  3. Freeman RG, Knox JM, Owens DW. Cutaneous lesions of lupus erythematosus induced by monochromatic light. Arch Dermatol 1969; 100:677.
  4. Cripps DJ, Rankin J. Action spectra of lupus erythematosus and experimental immunofluorescence. Arch Dermatol 1973; 107:563.
  5. Hölzle E, Plewig G, Lehmann P. Photodermatoses--diagnostic procedures and their interpretation. Photodermatol 1987; 4:109.
  6. Wolska H, Błaszczyk M, Jabłońska S. Phototests in patients with various forms of lupus erythematosus. Int J Dermatol 1989; 28:98.
  7. van Weelden H, Velthuis PJ, Baart de la Faille H. Light-induced skin lesions in lupus erythematosus: photobiological studies. Arch Dermatol Res 1989; 281:470.
  8. Lehmann P, Hölzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990; 22:181.
  9. Hymes SR, Russell TJ, Jordon RE. The anti-Ro antibody system. Int J Dermatol 1986; 25:1.
  10. Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 1988; 31:1007.
  11. Herrero C, Bielsa I, Font J, et al. Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases. J Am Acad Dermatol 1988; 19:1057.
  12. David KM, Thornton JC, Davis B, et al. Morbidity and mortality in patients with subacute cutaneous lupus erythematosus (SCLE) (abstract). J Invest Dermatol 1984; 82:408.
  13. Callen JP. Discoid lupus erythematosus--variants and clinical associations. Clin Dermatol 1985; 3:49.
  14. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001; 45:86.
  15. Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol 2011; 64:37.
  16. Stege H, Budde MA, Grether-Beck S, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol Photoimmunol Photomed 2000; 16:256.
  17. Herzinger T, Plewig G, Röcken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004; 50:3045.
  18. Callen JP, Roth DE, McGrath C, Dromgoole SH. Safety and efficacy of a broad-spectrum sunscreen in patients with discoid or subacute cutaneous lupus erythematosus. Cutis 1991; 47:130.
  19. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006; 24:348.
  20. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301:65.
  21. Boeckler P, Milea M, Meyer A, et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 2005; 152:265.
  22. Miot HA, Bartoli Miot LD, Haddad GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005; 211:118.
  23. Gallego H, Crutchfield CE 3rd, Lewis EJ, Gallego HJ. Report of an association between discoid lupus erythematosus and smoking. Cutis 1999; 63:231.
  24. Koskenmies S, Järvinen TM, Onkamo P, et al. Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus 2008; 17:337.
  25. Boeckler P, Cosnes A, Francès C, et al. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol 2009; 145:1012.
  26. Chasset F, Francès C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol 2015; 72:634.
  27. Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol 2011; 131:1981.
  28. Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012; 148:317.
  29. Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002; 11:71.
  30. Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed 2008; 24:260.
  31. Heine G, Lahl A, Müller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol 2010; 163:863.
  32. Cutillas-Marco E, Morales-Suárez-Varela M, Marquina-Vila A, Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010; 19:810.
  33. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006; 5:114.
  34. Renne J, Werfel T, Wittmann M. High frequency of vitamin D deficiency among patients with cutaneous lupus erythematosus [corrected]. Br J Dermatol 2008; 159:485.
  35. Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep 2011; 13:300.
  37. BJORNBERG A, HELLGREN L. Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment. Br J Dermatol 1963; 75:156.
  38. Bjornberg A, Hellgren L. Topical treatment of chronic discoid lupus erythematosus with betamethason-17-valerate and fluocinolone acetonie-a double blind study. Indian J Dermatol 1966; 12:17.
  39. Mitchell AD, Mitchell DM. Fluocinolone acetonide in the treatment of chronic discoid lupus erythematosus. Lancet 1962; 280:359.
  40. Roenigk HH Jr, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980; 25:281.
  41. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009; :CD002954.
  42. Böhm M, Gaubitz M, Luger TA, et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology 2003; 207:381.
  43. Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148:353.
  44. Sárdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 2009; 301:93.
  45. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008; 64:337.
  46. Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011; 65:54.
  47. Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 2009; 34:776.
  48. Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007; 156:191.
  49. Tlacuilo-Parra A, Guevara-Gutiérrez E, Gutiérrez-Murillo F, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005; 44:1564.
  50. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51:407.
  51. Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43:1383.
  52. Walker SL, Kirby B, Chalmers RJ. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 2002; 147:405.
  53. Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol 2010; 35:27.
  54. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10:365.
  55. Knott HM, Martínez JD. Innovative management of lupus erythematosus. Dermatol Clin 2010; 28:489.
  56. Callen JP. Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16:245.
  57. Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982; 118:412.
  58. Callen JP. Intralesional triamcinolone is effective for discoid lupus erythematosus of the palms and soles. J Rheumatol 1985; 12:630.
  59. Gunasekera V, Jayaram H, Kashani S, et al. Refractory discoid lupus erythematosis of the eyelid successfully treated with intra-lesional triamcinolone. Eye (Lond) 2008; 22:1205.
  60. Edwards AO. Central retinal artery occlusion following forehead injection with a corticosteroid suspension. Pediatr Dermatol 2008; 25:460.
  61. Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis 1991; 47:351.
  62. Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999; 41:1049.
  63. Ritschel WA, Hammer GV, Thompson GA. Pharmacokinetics of antimalarials and proposals for dosage regimens. Int J Clin Pharmacol Biopharm 1978; 16:395.
  64. McChesney EW RN. Comparative metabolic studies of chloroquine and hydroxychloroquine. Arthritis Rheum 1964; 7:328.
  65. Callen JP, Camisa C. Antimalarial agents. In: Comprehensive dermatologic drug therapy, 2nd ed, Wolverton SE (Ed), Elsevier Inc., Philadelphia 2007. p.259.
  66. Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.
  67. Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127:513.
  68. Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011; 147:1261.
  69. Yokogawa N, Eto H, Tanikawa A, et al. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. Arthritis Rheumatol 2017; 69:791.
  70. Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 2009; 18:735.
  71. Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189:425.
  72. Lipsker D, Piette JC, Cacoub P, et al. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995; 190:257.
  73. Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9:92.
  74. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42:983.
  75. Francès C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012; 148:479.